- Home
- INCR vs ANL Comparison
INCR vs ANL Comparison
Compare INCR & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCR
- ANL
- Stock Information
- Founded
- INCR 1994
- ANL 2004
- Country
- INCR Israel
- ANL Cayman Islands
- Employees
- INCR N/A
- ANL N/A
- Industry
- INCR Biotechnology: Pharmaceutical Preparations
- ANL
- Sector
- INCR Health Care
- ANL
- Exchange
- INCR Nasdaq
- ANL Nasdaq
- Market Cap
- INCR 76.7M
- ANL 81.9M
- IPO Year
- INCR N/A
- ANL 2023
- Fundamental
- Price
- INCR $1.60
- ANL $2.29
- Analyst Decision
- INCR
- ANL Strong Buy
- Analyst Count
- INCR 0
- ANL 2
- Target Price
- INCR N/A
- ANL $9.00
- AVG Volume (30 Days)
- INCR 29.6K
- ANL 8.6K
- Earning Date
- INCR 03-25-2025
- ANL 03-18-2025
- Dividend Yield
- INCR N/A
- ANL N/A
- EPS Growth
- INCR N/A
- ANL N/A
- EPS
- INCR N/A
- ANL N/A
- Revenue
- INCR $72,420,918.00
- ANL $5,000,000.00
- Revenue This Year
- INCR N/A
- ANL N/A
- Revenue Next Year
- INCR $39.30
- ANL N/A
- P/E Ratio
- INCR N/A
- ANL N/A
- Revenue Growth
- INCR N/A
- ANL N/A
- 52 Week Low
- INCR $1.17
- ANL $1.85
- 52 Week High
- INCR $3.72
- ANL $17.48
- Technical
- Relative Strength Index (RSI)
- INCR 46.96
- ANL 54.82
- Support Level
- INCR $1.54
- ANL $2.05
- Resistance Level
- INCR $1.62
- ANL $2.42
- Average True Range (ATR)
- INCR 0.05
- ANL 0.15
- MACD
- INCR -0.00
- ANL 0.01
- Stochastic Oscillator
- INCR 31.45
- ANL 57.45
About INCR Intercure Ltd.
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. The products are distributed to hospitals, pharmacies, research, and government organizations. The company has two segments namely: Cannabis segment and Biomed segment, out of which it derives maximum revenue from Cannabis segment.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.